Fertility Tech Market Expands, With Memphasys Ready to Capitalise

The global assisted reproductive technology (ART) sector continues to grow rapidly, with IVF cycles projected to exceed 4 million annually by 2030. The demand for technologies that improve embryo success rates is stronger than ever — and Memphasys (ASX:MEM) with its Felix™ System appears poised to leverage this demand.

Clinical Trial Confirms Best-In-Class Performance

Memphasys has announced the successful unblinding and data analysis of its pivotal clinical trial for the Felix™ System, conducted in partnership with Monash IVF. The trial confirmed Felix’s ability to meet and exceed key industry benchmarks.

“The successful completion of the Felix™ System clinical trial marks a defining moment for Memphasys,” said CEO Dr. David Ali.

The primary endpoint — the embryo utilisation rate — was achieved, with the Felix™ System proving non-inferior to the well-established Swim-Up method and statistically superior to Density Gradient Centrifugation (DGC), the most widely used sperm preparation technique globally.

Faster, Safer, and Preferred by Lab Staff

In addition to strong clinical results, the Felix™ System outperformed existing methods on efficiency. The system was found to be significantly faster at isolating sperm than both DGC and Swim-Up.

“Not only has the Felix™ System demonstrated comparable or superior performance to traditional methods, but it has also achieved the ultimate benchmark — improving embryo utilisation rates,” Dr. Ali added.

The study also recorded zero adverse events, with safety confirmed throughout.

Importantly, laboratory staff strongly favoured the system. A full 100 per cent of users preferred Felix™ over DGC, and more than half preferred it over Swim-Up.

Regulatory Momentum Builds

With clinical validation in hand, Memphasys is preparing data submissions for the European Conformity (CE) Mark in Europe, alongside pathways for regulatory approvals in Australia (TGA) and India (CDSCO). Successful registration will unlock access to major markets, including regions with mutual conformity recognition agreements like Japan, Canada, the US, and Switzerland.

“As we continue advancing regulatory approvals and market entry strategies, our goal remains clear — to establish the Felix™ System as the gold standard in ART,” said Dr. Ali.

Commercial Rollout Begins in Key Regions

Memphasys is not starting from scratch. The company has existing distribution agreements with Vitrolife in Japan, Canada, and New Zealand. In Japan, Felix™ has already been undergoing real-world testing for over 12 months, with sales expected to accelerate following the trial confirmation.

“With our existing distribution agreements in place and growing interest from strategic partners, Memphasys is now in a strong position to drive market expansion,” Dr. Ali said.

The company also holds a Letter of Intent with Heranova in China, where utilisation testing is underway, and has recorded Research and Development (R&D) sales in the UAE.

Rigorous Study Positions Memphasys for Growth

The Felix™ clinical trial is considered the most rigorous study ever conducted for a sperm selection device.

“The rigor of this study sets the Felix™ System apart from any other sperm separation technology on the market,” Dr. Ali emphasised.

Memphasys plans to submit the trial results to peer-reviewed scientific journals, further boosting its industry credibility.

Next Steps

The company is currently advancing regulatory submissions and expanding commercial discussions with distributors and ART clinics globally. In particular, special access market segments will be prioritised while regulatory approvals progress.

“We look forward to updating shareholders as we progress our commercial rollout,” Dr. Ali concluded.